![](https://cpathdev3.lotosnile.com/wp-content/uploads/2013/05/news_bkg-1080x176.jpg)
News
Home>News & Events>Videos>C-Path>Dr. Janet Woodcock, Director, Center for Drug Evaluation and Research, on FDA’s Critical Path Initiative
87
Related Posts
-
Evidentiary Considerations for Integration of Biomarkers in Drug Development Symposium
-
Dr. Brumfield’s Remarks at Partnering for Cures
-
WHO Collaborative registration procedure of prequalified medicines
-
Brian Harvey, VP, U.S. Regulatory Policy at Sanofi, speaks on panel at Partnering for Cures Nov. 8, 2011